A Phase 2 interventional study of pembrolizumab and ACP-196 in combination with pembrolizumab in Metastatic Urothelial Carcinoma, sponsored by Acerta Pharma BV. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-10.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing pembrolizumab in Carcinoma, Transitional Cell — 9 open to participants now, 13 under way, 3 of them phase 3. pembrolizumab · Carcinoma, Transitional Cell.
Among the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell, this one is the 8th largest by enrollment, is one of 3 that started in 2015, is one of 19 in phase 2, and was the 1st registered.
633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →9 of the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell are open now, in 4 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Canada, Korea, Republic of and 1 more country
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is given beside the treatment under test here, not tested itself. Read study by study →
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 21 · Phase 3 3
First in 2015; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is above the median of 50 across 499 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 31 across the 28 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
AstraZeneca has 5 studies filed under Carcinoma, Transitional Cell — fewer than ten, so there is no comparison to draw.
3 of the studies testing pembrolizumab in Carcinoma, Transitional Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05406713Matthew GalskyPembrolizumab in Muscle-invasive Bladder Cancer | 2027-01-31 |
| NCT04724018Dana-Farber Cancer InstituteSacituzumab Govitecan Plus EV in Metastatic UC | 2027-02-01 |
| NCT05239624Memorial Sloan Kettering Cancer CenterEnfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies testing pembrolizumab in Carcinoma, Transitional Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Metastatic Urothelial Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm 1: pembrolizumab monotherapy
Drug: pembrolizumab
Arm 2: ACP-196 in combination with pembrolizumab
Drug: ACP-196 in combination with pembrolizumab
Drug pages: Acalabrutinib · Pembrolizumab
Number of Participants With Overall Response
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: Every 12 weeks for up to 2 years.
| Milestone | Arm 1: Pembrolizumab Monotherapy | Arm 2- Acalabrutinib+Pembrolizumab |
|---|---|---|
| Started | 38 | 40 |
| Enrolled | 38 | 40 |
| Received study medication | 35 | 40 |
| Discontinued study | 38 | 40 |
| Completed | 0 | 0 |
| Not completed | 38 | 40 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
| Participants | Pembrolizumab | ACP-196 in Combination With Pembrolizumab |
|---|---|---|
| Number of Participants With Overall Response | 9 | 8 |
Collected over Reported Adverse Events (AEs) include events starting on or after Day 0 and on or before Day 730.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 - Pembrolizumab Monotherapy | 25/35 (71.4%) | 15/35 (42.9%) | 34/35 (97.1%) |
| Arm 2 - Acalabrutinib+Pembrolizumab | 31/40 (77.5%) | 23/40 (57.5%) | 39/40 (97.5%) |
| Event | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib+Pembrolizumab |
|---|---|---|
| Acute Kidney DiseaseRenal and urinary disorders | 2/35 | 5/40 |
| SepsisInfections and infestations | 1/35 | 3/40 |
| NauseaGastrointestinal disorders | 2/35 | 0/40 |
| Urinary Tract InfectionInfections and infestations | 2/35 | 2/40 |
| PneumoniaInfections and infestations | 2/35 | 1/40 |
| AscitesGastrointestinal disorders | 0/35 | 2/40 |
| HaematuriaRenal and urinary disorders | 1/35 | 2/40 |
| VomitingGastrointestinal disorders | 1/35 | 0/40 |
| DiarrheaGastrointestinal disorders | 1/35 | 0/40 |
| Impaired Gastric EmptyingGastrointestinal disorders | 1/35 | 0/40 |
| Event | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib+Pembrolizumab |
|---|---|---|
| FatigueGeneral disorders | 16/35 | 34/40 |
| DiarrheaGastrointestinal disorders | 7/35 | 16/40 |
| Decreased AppetiteMetabolism and nutrition disorders | 14/35 | 16/40 |
| Alanine Aminotransferase IncreasedInvestigations | 3/35 | 14/40 |
| AnaemiaBlood and lymphatic system disorders | 8/35 | 13/40 |
| VomitingGastrointestinal disorders | 10/35 | 13/40 |
| NauseaGastrointestinal disorders | 11/35 | 10/40 |
| ConstipationGastrointestinal disorders | 5/35 | 12/40 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/35 | 12/40 |
| Aspartate Aminotransferase IncreasedInvestigations | 2/35 | 11/40 |
| Age, Continuous(Years) | Pembrolizumab | ACP-196 in Combination With Pembrolizumab | Total |
|---|---|---|---|
| Mean | 65.8 ± 11.08 | 66.4 ± 8.53 | 66.1 ± 9.74 |
| Sex: Female, Male(Participants) | Pembrolizumab | ACP-196 in Combination With Pembrolizumab | Total |
|---|---|---|---|
| Female | 28 | 29 | 57 |
| Male | 7 | 11 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Pembrolizumab | ACP-196 in Combination With Pembrolizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 34 | 40 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Pembrolizumab | ACP-196 in Combination With Pembrolizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 32 | 37 | 69 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2015 to primary completion in Feb 2018, 34 months.
Results were first posted in Sep 2019, 1 year 7 months after primary completion.
Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acalabrutinib · Pembrolizumab
Carcinoma, Transitional Cell →